JPH0422351A - Dissolutive therapy device - Google Patents
Dissolutive therapy deviceInfo
- Publication number
- JPH0422351A JPH0422351A JP2129834A JP12983490A JPH0422351A JP H0422351 A JPH0422351 A JP H0422351A JP 2129834 A JP2129834 A JP 2129834A JP 12983490 A JP12983490 A JP 12983490A JP H0422351 A JPH0422351 A JP H0422351A
- Authority
- JP
- Japan
- Prior art keywords
- catheter
- gallbladder
- ultrasonic
- medicine
- vibration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000004090 dissolution Methods 0.000 claims abstract description 19
- 239000012530 fluid Substances 0.000 claims abstract description 12
- 239000008155 medical solution Substances 0.000 claims description 5
- 210000000232 gallbladder Anatomy 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 4
- 230000005484 gravity Effects 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 230000005855 radiation Effects 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 210000001124 body fluid Anatomy 0.000 description 13
- 239000010839 body fluid Substances 0.000 description 13
- 208000001130 gallstones Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000001883 cholelithiasis Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940037959 monooctanoin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Surgical Instruments (AREA)
- External Artificial Organs (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は溶解治療装置、更に詳しくは、生体内の凝塊物
を溶解、または溶解を促進補助する薬液を体内の凝塊物
の周囲に導入し、凝塊物の溶解後その溶解成分を体外へ
回収する溶解治療装置に関する。Detailed Description of the Invention [Industrial Application Field] The present invention relates to a dissolution treatment device, and more specifically, a method for dissolving a coagulum in a living body or dissolving a medicinal solution around a coagulum in the body. The present invention relates to a dissolution treatment device that introduces a coagulum, dissolves the coagulum, and then recovers the dissolved components from the body.
［従来の技術］
従来、生体内の胆嚢等の治療部位へモノオクタノイン、
ｄ−リモネン或いはメチル上ブチルエーテル（ＭＴＢＥ
）等の結石溶解剤である薬液を注入し、一定時間放置し
、該薬液により治療部に存在する結石等の凝塊物を溶解
し、この凝塊物が溶解された薬液等の流体を吸引するこ
とにより、該結石等を除去する治療を行う溶解治療装置
が考えられている。[Conventional technology] Conventionally, monooctanoin,
d-limonene or methyl butyl ether (MTBE)
) is injected and left to stand for a certain period of time, the drug dissolves the stones and other agglomerates present in the treatment area, and the medicinal solution and other fluid in which the agglomerates have been dissolved is aspirated. A dissolving treatment device has been proposed that performs treatment to remove stones and the like by doing so.
前記溶解治療装置としては、例えば特開昭６２−１１７
５４５号公報において、ポンプを用いて生体内の胆嚢等
の治療部位へ一定量の薬液を注入・吸引して撹拌し、そ
の溶解を促進するようにしたものが提案されている。As the dissolution treatment device, for example, Japanese Patent Application Laid-Open No. 62-117
No. 545 proposes a system in which a pump is used to inject and aspirate a certain amount of a medicinal solution into a treatment site, such as the gallbladder, in a living body, and stir it to promote its dissolution.
また、特開昭６３−４０５４１号公報においては、前述
した溶解治療装置に、更に、胆嚢内の圧力を検出し、同
胆嚢内の圧力を設定範囲内に保持するように薬液の注入
・吸引を制御する手段を備えたものが提案されている。Furthermore, in Japanese Patent Application Laid-open No. 63-40541, the above-mentioned dissolution treatment device is further equipped with a system that detects the pressure within the gallbladder and injects and suctions a medicinal solution to maintain the pressure within the gallbladder within a set range. Some have been proposed that include means for controlling.
しかし、前述した溶解治療装置では、前記凝塊物を溶解
する薬液を注入及び吸引を繰り返す撹拌によって境界物
の溶解を行うため、該溶解物を溶解するなめには相当の
時間を必要とする。However, in the above-mentioned dissolution treatment device, the boundary object is dissolved by stirring repeatedly by injecting and suctioning the chemical solution that dissolves the coagulum, and therefore it takes a considerable amount of time to dissolve the agglomerate.
そのため、前記治療部位へ例えば超音波により振動を与
える超音波アプリケータ等の振動波発生手段を併せて用
いる溶解治療装置が考えられている。Therefore, a dissolution treatment device is being considered that also uses a vibration wave generating means such as an ultrasonic applicator that applies vibrations to the treatment area using ultrasound, for example.
［発明が解決しようとする課題］
しかし、前述した溶解治療装置では、前記生体の外から
治療部位へ振動波を与えるため、強力な振動波を与えよ
うとする場合、前記超音波アプリケータの形状が大きく
なり操作性が悪く、また、前記超音波アプリケータに内
設された超音波振動子の例えば前面のみのエネルギーだ
けを前記治療部位へ与えるため、該超音波振動子のエネ
ルギーが十分に用いられていないという問題点がある。[Problems to be Solved by the Invention] However, in the above-described dissolution treatment device, vibration waves are applied from outside the living body to the treatment site, so when applying strong vibration waves, the shape of the ultrasonic applicator The energy of the ultrasonic transducer becomes large, resulting in poor operability.Also, since only the energy of, for example, the front side of the ultrasonic transducer installed in the ultrasonic applicator is applied to the treatment area, the energy of the ultrasonic transducer is not fully used. The problem is that it has not been done.
本発明は前述した点にかんがみてなされたもので、超音
波振動子のエネルギーを効率良く治療部位へ与えること
ができる溶解治療装置を提供することを目的としている
。The present invention has been made in view of the above-mentioned points, and an object of the present invention is to provide a dissolution treatment device that can efficiently apply the energy of an ultrasonic transducer to a treatment site.
［課題を解決するための手段］
本発明の溶解治療装置は、生体内の凝塊物を溶解する薬
液を該生体内に注入すると共に、前記薬液を含む流体を
前記生体内から吸引するカテーテルと、前記生体の前記
薬液注入部位に振動波を与えると共に、前記カテーテル
を振動させる振動波照射手段とを備えている。[Means for Solving the Problems] The dissolution treatment device of the present invention includes a catheter that injects into the living body a medicinal solution that dissolves coagulum in the living body and aspirates fluid containing the medicinal solution from the living body. and vibration wave irradiation means for applying vibration waves to the drug solution injection site of the living body and vibrating the catheter.
［作用］
前述した構成により、前記超音波照射手段の振動が前記
カテーテルの先端部へ伝達されるようにしている。[Operation] With the above-described configuration, the vibration of the ultrasonic irradiation means is transmitted to the distal end portion of the catheter.
［実施例〕 以下、図面を参照して本発明の詳細な説明する。[Example〕 Hereinafter, the present invention will be described in detail with reference to the drawings.
第１図及び第２図は本発明の一実施例に係わり、第１図
は溶解治療装置の概略の構成を示すブロック図、第２図
は超音波アプリケータの要部断面図である。FIGS. 1 and 2 relate to one embodiment of the present invention, with FIG. 1 being a block diagram showing a schematic configuration of a dissolution treatment device, and FIG. 2 being a sectional view of essential parts of an ultrasonic applicator.
溶解治療装置は、第１図に示すように、人体２の治療部
位である例えば胆１１３へ経皮的に挿通され、凝塊物で
ある例えば結石４を溶解するための溶解剤を注入すると
共に、該胆嚢３から流体を吸引する硬性の例えば金属パ
イプにより形成されたカテーテル５と、このカテーテル
５とチューブ６により連通し、前記溶解剤を注入或いは
前記流体を吸引するための注入・吸引ポンプ７と、前記
吸引ポンプ７に、溶解剤が入れられた薬液槽８或いは前
記胆嚢３から吸引された流体を蓄積する排液槽９を接続
するための切換弁１０と、前記注入・吸引ポンプ７及び
前記切換弁１ｏを制御し、前記胆嚢３への薬液の注入或
いは前記胆嚢３がらの流体の吸引を制御する制御装置１
１と、前記人体２の体表面に当接し、前記胆Ｉａ４へ振
動波である例えば超音波を照射する超音波振動子１２が
内設された超音波アプリケータ１３と、前記超音波振動
子１２を駆動する超音波駆動回路１４と、前記超音波ア
プリケータ１３を前記人体２の体表面に当接するように
支持するアプリケータ支持部１５とから構成されるよう
になっている。As shown in FIG. 1, the dissolution treatment device is percutaneously inserted into the treatment site of the human body 2, such as the gallbladder 113, and injects a dissolving agent for dissolving a coagulum, such as a stone 4. , a catheter 5 formed of a hard metal pipe, for example, for aspirating fluid from the gallbladder 3, and an injection/suction pump 7 communicating with the catheter 5 through a tube 6 for injecting the lysing agent or suctioning the fluid. , a switching valve 10 for connecting the suction pump 7 with a drug solution tank 8 containing a dissolving agent or a drainage tank 9 that accumulates fluid sucked from the gallbladder 3; A control device 1 that controls the switching valve 1o and controls the injection of a medicinal solution into the gallbladder 3 or the suction of fluid from the gallbladder 3.
1, an ultrasonic applicator 13 equipped with an ultrasonic transducer 12 that comes into contact with the surface of the human body 2 and irradiates vibration waves, such as ultrasonic waves, to the bile Ia4, and the ultrasonic transducer 12. and an applicator support section 15 that supports the ultrasonic applicator 13 so as to come into contact with the surface of the human body 2.
前記超音波駆動回路１４は、前記超音波アプリケータ１
３へコネクタ１６により接続され、このコネクタ１６に
接続された信号線１７ａ、１７ｂにより前記超音波振動
子１２へ接続されている。The ultrasonic drive circuit 14 drives the ultrasonic applicator 1
3 through a connector 16, and is connected to the ultrasonic transducer 12 through signal lines 17a and 17b connected to this connector 16.
前記超音波振動子１２は、例えばボルト締めランシュ板
振動子であり、該超音波振動子１２の前記生体２の体表
面側には振動部材１８が配設され、この振動部材１８の
前記生体２の体表面側の放射面１９には水等の超音波伝
達液が充填されたウォータバック２０が配設されている
。また、前記超音波振動子１２の前記生体２の体表面と
反対面にはバックマス２１が配設され、このバックマス
２１はナツト２２及びボルト２３により前記超音波アプ
リケータ１３の外装面に支持されている。The ultrasonic transducer 12 is, for example, a bolted Lanche plate transducer, and a vibrating member 18 is disposed on the body surface side of the living body 2 of the ultrasonic transducer 12. A water bag 20 filled with an ultrasonic transmission liquid such as water is disposed on the radiation surface 19 on the body surface side. Further, a back mass 21 is disposed on the opposite surface of the ultrasound transducer 12 from the body surface of the living body 2, and this back mass 21 is supported on the exterior surface of the ultrasound applicator 13 by nuts 22 and bolts 23. has been done.
前記超音波振動子１２、振動部材１８及びバックマス２
１には後述するように孔が形成され、この孔に前記カテ
ーテル５が挿通されるようになっている。The ultrasonic transducer 12, the vibrating member 18, and the back mass 2
A hole is formed in 1 as described later, and the catheter 5 is inserted through this hole.
前記バックマス２１、ナツト２２及びボルト２３に関連
する要部について第２図を用いて説明する。The main parts related to the back mass 21, nut 22, and bolt 23 will be explained using FIG. 2.
前記バックマス２１には、前記ナツト２２が螺合するネ
ジ部２１ａ及び前記ボルト２３が螺合するネジ部２１ｂ
が形成されると共に、このネジ部２１ａ、２１ｂの略中
心位置に孔２１′が穿設されている。The back mass 21 has a threaded portion 21a into which the nut 22 is threaded, and a threaded portion 21b into which the bolt 23 is threaded.
are formed, and a hole 21' is bored approximately at the center of the threaded portions 21a, 21b.
前記孔２１“には、前記つオータバツク２０の外周部材
である膜２０′及び前記カテーテル５が挿通され、前記
膜２０゛及び前記カテーテル５の端部は、前記ネジ部２
１ｂの上端部で折り曲げられ、前記ネジ部２１ｂの上端
面と前記ボルト２３と咬合により、前記バックマス２１
に固定されるようになっている。The membrane 20', which is an outer peripheral member of the overbag 20, and the catheter 5 are inserted into the hole 21'', and the membrane 20'' and the end of the catheter 5 are inserted into the threaded portion 2.
The back mass 21 is bent at the upper end portion of the threaded portion 21b, and the upper end surface of the threaded portion 21b engages with the bolt 23.
It is now fixed to .
また、前記ボルト２３は、前記ネジ部２１ｂと螺合する
面の反対面が突出し、更に、該ボルト２３の略中心位置
には、前記カテーテル５と連通するように孔２３′が形
成され、前述した突出した部分に前記チューブ６が接続
され、前記チューブ６と前記カテーテル５とが連通する
ようになっている。Further, the bolt 23 has a protruding surface opposite to the surface that is screwed into the threaded portion 21b, and a hole 23' is formed approximately at the center of the bolt 23 so as to communicate with the catheter 5. The tube 6 is connected to the protruding portion, so that the tube 6 and the catheter 5 communicate with each other.
前記制御装置ｔ１１は、前記切換弁１０を前記薬液槽８
及び前記注入・吸引ポンプ７を接続するように制御し、
前記注入・吸引ポンプ７に対して前記薬液槽８内の溶解
剤を前記切換弁１０、前記チューブ６、前記ボルト２３
及び前記カテーテル５を介して前記胆嚢３へ注入するよ
うにすると共に、前記切換弁１０を前記排液槽９及び前
記注入・吸引ポンプ７を接続するように制御し、前記注
入・吸引ポンプ７を制御し前記胆嚢３から流体を前記カ
テーテル５、前記ボルト２３、前記チューブ６及び前記
切換弁１０を介して前記排液槽９へ吸弓するようになっ
ている。The control device t11 connects the switching valve 10 to the chemical tank 8.
and controlling the injection/suction pump 7 to be connected;
The dissolving agent in the chemical tank 8 is transferred to the injection/suction pump 7 through the switching valve 10, the tube 6, and the bolt 23.
and inject into the gallbladder 3 via the catheter 5, and control the switching valve 10 to connect the drainage tank 9 and the injection/suction pump 7, and control the injection/suction pump 7. The fluid is controlled to be sucked from the gallbladder 3 to the drainage tank 9 via the catheter 5, the bolt 23, the tube 6, and the switching valve 10.
このように構成された溶解治療装置の作用について説明
する。The operation of the dissolution treatment device configured as described above will be explained.
前記超音波駆動回路１４は、駆動信号を前記コネクタ１
６及び前記信号線１７ａ、１７ｂを介して、前記超音波
振動子１２へ供給し、これにより前記超音波振動子１２
が振動する。The ultrasonic drive circuit 14 sends a drive signal to the connector 1.
6 and the signal lines 17a and 17b to the ultrasonic transducer 12, thereby causing the ultrasonic transducer 12 to
vibrates.
前記超音波振動子１２の振動は、前記振動部材１８に伝
達され、該振動部材１８の前記放射面１９から前記ウォ
ータバック２０及び前記人体２の体表を介して前記胆嚢
３へ伝達される。The vibrations of the ultrasonic transducer 12 are transmitted to the vibrating member 18 , and from the radiation surface 19 of the vibrating member 18 to the gallbladder 3 via the water bag 20 and the surface of the human body 2 .
更に、前記超音波振動子１２の振動は、前記バックマス
２１に伝達され、該バックマス２１が振動することによ
り、該バックマス２１に固定された前記カテーテル５の
基部側が振動する。Further, the vibration of the ultrasonic transducer 12 is transmitted to the back mass 21, and as the back mass 21 vibrates, the proximal side of the catheter 5 fixed to the back mass 21 vibrates.
前記カテーテル５の基部側の振動は、前記胆嚢３内に位
置する該カテーテル５の先端部へ伝達される。Vibrations on the proximal side of the catheter 5 are transmitted to the distal end of the catheter 5 located within the gallbladder 3.
これにより、前記カテーテル５の先端部近傍には、該カ
テーテル５の振動による振動波が発生し、この振動波は
前記胆石４に及び、該胆石４の破壊が促進される。As a result, a vibration wave is generated near the distal end of the catheter 5 due to the vibration of the catheter 5, and this vibration wave reaches the gallstone 4, and the destruction of the gallstone 4 is promoted.
なお、前記カテーテル５を前記胆石４に接触させ、該カ
テーテル５の振動を直接伝達するようにし、該胆石４の
破壊を促進するようにしてもよい。Incidentally, the destruction of the gallstones 4 may be promoted by bringing the catheter 5 into contact with the gallstones 4 and transmitting the vibrations of the catheter 5 directly.
また、前記カテーテル５に振動を伝える必要が無い場合
、該カテーテル５を軟性の例えば合成樹脂により形成さ
れたものを用いればよい。Furthermore, if there is no need to transmit vibrations to the catheter 5, the catheter 5 may be made of soft material such as synthetic resin.
即ち、従来用いられていなかった、超音波振動子の生体
と反対面に放射される振動波を有効に用いることができ
るという効果がある。That is, there is an effect that the vibration waves emitted from the surface of the ultrasonic transducer opposite to the living body, which has not been used in the past, can be effectively used.
ところで、第３図（Ａ）に示すように、人体３２の治療
部位である例えば胆嚢３３に薬液３９を注入した場合に
、該胆嚢３３に胆汁等の体液３８が流入すると、前記体
液３８の方が前記薬液３９に対して比重が大きいため、
該体液３８が前記膜１１３３の底部に沈んでしまい、前
記薬液３９が凝塊物である例えば胆石３４の周囲に行き
渡らないことがある。そのため、薬液３９の注入を繰り
返しても前記胆石３４は溶解されない。By the way, as shown in FIG. 3(A), when a medical solution 39 is injected into a treatment site of a human body 32, for example, a gallbladder 33, when a body fluid 38 such as bile flows into the gallbladder 33, the body fluid 38 is has a higher specific gravity than the chemical solution 39,
The body fluid 38 may sink to the bottom of the membrane 1133, and the medical solution 39 may not be distributed around clots such as gallstones 34. Therefore, even if the medicinal solution 39 is repeatedly injected, the gallstones 34 are not dissolved.
そこで、体液３８が有るか否か、及び、体液３８がある
場合は、該体液３８の前記胆嚢３３内に占める量が術者
に認識できれば該体液３８を吸引する等、適切な治療処
置を行うことができる。Therefore, if the operator can recognize whether or not there is body fluid 38 and, if there is body fluid 38, the amount of body fluid 38 that occupies the gallbladder 33, appropriate therapeutic measures such as aspirating the body fluid 38 are performed. be able to.
そこで、前記薬液３９に、該薬液３９よつも比重が大き
く、且つ、前記体液３８よりも比重が小さいマイクロカ
プセル化した超音波反射体４０を含有させ、前記胆嚢３
３へ超音波アプリゲータ３５内を挿通されたカテーテル
３６を介して注入するようにしている。これにより、前
記超音波反射体４０は、前記体液３８と前記薬液３９と
の境界に位置するようになる。Therefore, the medicinal solution 39 is made to contain a micro-encapsulated ultrasonic reflector 40 which has a higher specific gravity than the medicinal solution 39 and a smaller specific gravity than the body fluid 38, and the gallbladder 3
3 through a catheter 36 inserted through an ultrasonic applicator 35. Thereby, the ultrasonic reflector 40 is located at the boundary between the body fluid 38 and the medical fluid 39.
前述した状況を、図示しない例えばデジタル・スキャン
・コンバータを内設した超音波観測装置に接続された超
音波プローブ３６により観測すると、該超音波プローブ
３６の観測範囲４１の状況が、例えば第３図（Ｂ）に示
すように、前記超音波観測装置のモニタ画面４２上に、
観測画面４１として映しだされ、この観測画面４１′内
に、前記胆１１３３の像３３°、前記胆石３４′の像及
び前記超音波反射体４０の像４０″が映しだされる。When the above-mentioned situation is observed by an ultrasonic probe 36 connected to an ultrasonic observation device (not shown) equipped with a digital scan converter, for example, the situation in the observation range 41 of the ultrasonic probe 36 is as shown in FIG. 3, for example. As shown in (B), on the monitor screen 42 of the ultrasound observation device,
This is displayed as an observation screen 41, and within this observation screen 41', an image 33° of the gall 1133, an image of the gallstone 34', and an image 40'' of the ultrasonic reflector 40 are displayed.
従って、術者は前記超音波反射体４０の像４０′により
前記体液３８と前記薬液３９との境界を認識することが
できる。Therefore, the operator can recognize the boundary between the body fluid 38 and the medical fluid 39 from the image 40' of the ultrasound reflector 40.
また、空気等の気体は、超音波を比較的多く反射するの
で、例えば第４図に示すように、溶解剤である前記薬液
３９が入れられている薬液槽４３と、この薬液Ｉ！４３
に入れられた前記薬液を前記カテーテル３６を介して前
記胆嚢３３へ注入するポンプ４５との間に、前記薬液３
９に例えば空気等の気体を加圧混入する加圧装ｆｆ４４
を介挿し、この加圧装置４４により気体が混入された薬
液３９を前記胆嚢３３へ注入するようにする。Furthermore, since gases such as air reflect a relatively large amount of ultrasonic waves, for example, as shown in FIG. 43
The medicinal solution 3 is injected into the gallbladder 33 via the catheter 36, and
A pressurizing device ff44 that pressurizes and mixes gas such as air into 9.
is inserted, and the medical solution 39 mixed with gas is injected into the gallbladder 33 by this pressurizing device 44.
前述した状況を、前記超音波プローブ３７により観測す
ると、前記薬液３９に混入された気泡により、前記超音
波反射体４０を用いた場合と同様に術者は前記薬液３９
と前記体液３８との境界をを認識し、適切な処置を講じ
ることができる。When the above-mentioned situation is observed with the ultrasonic probe 37, the bubbles mixed in the chemical solution 39 cause the operator to
By recognizing the boundary between the body fluid 38 and the body fluid 38, appropriate measures can be taken.
なお、前記超音波アプリケータ３５には、前記胆石３３
の溶解を促進する振動波を放射する超音波振動子が内設
されている。また、前記カテーテル３６は、前記超音波
アプリケータ３５に挿通されること無く、別の位置から
前記胆嚢３３に挿入されてもよく、また、この場合、前
記超音波アプリケータ３５を用いなくてもよい。Note that the ultrasonic applicator 35 has the gallstone 33
An ultrasonic vibrator that emits vibration waves that promotes the dissolution of the liquid is installed inside. Further, the catheter 36 may be inserted into the gallbladder 33 from another position without being inserted through the ultrasound applicator 35, and in this case, the ultrasound applicator 35 may not be used. good.
［発明の効果］
以上説明したように本発明によれば、治療部位の外部か
ら凝塊物へ振動波を与えるのみならず、治療部位内で凝
塊物へ振動波を与えることができ、凝塊物の溶解及び破
壊を促進し、治療時間が短時間となり患者の苦痛を和ら
げることができるという効果がある。[Effects of the Invention] As explained above, according to the present invention, it is possible not only to apply vibration waves to the coagulum from the outside of the treatment area, but also to apply vibration waves to the coagulum within the treatment site. It has the effect of promoting the dissolution and destruction of lumps, shortening treatment time, and relieving patient pain.
第１図及び第２図は本発明の第一実施例に係わり、第１
図は溶解治療装置の概略の構成を示すブロック図、第２
図は超音波アプリケータの要部断面図、第３図及び第４
図は薬液と体液との境界を識別する手段の説明図である
。
５・カテーテル １２・・・超音波振動子１３・・
・超音波アプリケータ
第２図
第３図（Ａ）
第３図（Ｂ）
手続補正書（自発）
１．事件の表示
平成２年特許願第１２９８３４号
２、発明の名称
溶解治療装置
３、補正をする者
事件とグ泗用系FIG. 1 and FIG. 2 relate to the first embodiment of the present invention.
The figure is a block diagram showing the general configuration of the dissolution treatment device.
The figures are cross-sectional views of the main parts of the ultrasonic applicator, Figures 3 and 4.
The figure is an explanatory diagram of means for identifying the boundary between medical fluid and body fluid. 5. Catheter 12... Ultrasonic transducer 13...
・Ultrasonic applicator Figure 2 Figure 3 (A) Figure 3 (B) Procedural amendment (voluntary) 1. Indication of the case 1990 Patent Application No. 129834 2, Title of the invention Dissolution treatment device 3, Person making the amendment Case and the system of use
Claims (1)
共に、前記薬液を含む流体を前記生体内から吸引するカ
テーテルと、 前記生体の前記薬液注入部位に振動波を与えると共に、
前記カテーテルを振動させる振動波照射手段とを備えた
ことを特徴とする溶解治療装置。[Scope of Claims] A catheter that injects into the living body a medical solution that dissolves clots in the living body and sucks fluid containing the medical solution from the living body; along with giving
A dissolution treatment device comprising: vibration wave irradiation means for vibrating the catheter.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2129834A JPH0422351A (en) | 1990-05-17 | 1990-05-17 | Dissolutive therapy device |
| US07/589,945 US5273027A (en) | 1990-03-27 | 1990-09-28 | Method for dissolving a thickened mass within a living body and dissolving therapeutic apparatus for same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2129834A JPH0422351A (en) | 1990-05-17 | 1990-05-17 | Dissolutive therapy device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0422351A true JPH0422351A (en) | 1992-01-27 |
Family
ID=15019383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2129834A Pending JPH0422351A (en) | 1990-03-27 | 1990-05-17 | Dissolutive therapy device |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0422351A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016087334A (en) * | 2014-11-11 | 2016-05-23 | 富士機械製造株式会社 | Specification method and specification device |
| JP2018519061A (en) * | 2015-06-24 | 2018-07-19 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Tissue disruption therapy system and method for the treatment of brain tissue |
| US11364042B2 (en) | 2005-09-22 | 2022-06-21 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| US11432900B2 (en) | 2013-07-03 | 2022-09-06 | Histosonics, Inc. | Articulating arm limiter for cavitational ultrasound therapy system |
| US11648424B2 (en) | 2018-11-28 | 2023-05-16 | Histosonics Inc. | Histotripsy systems and methods |
| US11813485B2 (en) | 2020-01-28 | 2023-11-14 | The Regents Of The University Of Michigan | Systems and methods for histotripsy immunosensitization |
| US11819712B2 (en) | 2013-08-22 | 2023-11-21 | The Regents Of The University Of Michigan | Histotripsy using very short ultrasound pulses |
-
1990
- 1990-05-17 JP JP2129834A patent/JPH0422351A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364042B2 (en) | 2005-09-22 | 2022-06-21 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| US11701134B2 (en) | 2005-09-22 | 2023-07-18 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
| US11432900B2 (en) | 2013-07-03 | 2022-09-06 | Histosonics, Inc. | Articulating arm limiter for cavitational ultrasound therapy system |
| US11819712B2 (en) | 2013-08-22 | 2023-11-21 | The Regents Of The University Of Michigan | Histotripsy using very short ultrasound pulses |
| JP2016087334A (en) * | 2014-11-11 | 2016-05-23 | 富士機械製造株式会社 | Specification method and specification device |
| JP2018519061A (en) * | 2015-06-24 | 2018-07-19 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Tissue disruption therapy system and method for the treatment of brain tissue |
| US11135454B2 (en) | 2015-06-24 | 2021-10-05 | The Regents Of The University Of Michigan | Histotripsy therapy systems and methods for the treatment of brain tissue |
| US11648424B2 (en) | 2018-11-28 | 2023-05-16 | Histosonics Inc. | Histotripsy systems and methods |
| US11813484B2 (en) | 2018-11-28 | 2023-11-14 | Histosonics, Inc. | Histotripsy systems and methods |
| US11980778B2 (en) | 2018-11-28 | 2024-05-14 | Histosonics, Inc. | Histotripsy systems and methods |
| US11813485B2 (en) | 2020-01-28 | 2023-11-14 | The Regents Of The University Of Michigan | Systems and methods for histotripsy immunosensitization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7429249B1 (en) | Method for cavitation-induced tissue healing with low intensity ultrasound | |
| US8012092B2 (en) | Method of using a combination imaging and therapy transducer to dissolve blood clots | |
| US6113570A (en) | Method of removing thrombosis in fistulae | |
| US6013048A (en) | Ultrasonic assisted liposuction system | |
| US4917095A (en) | Ultrasound location and therapy method and apparatus for calculi in the body | |
| US9198680B2 (en) | Combination imaging and therapy transducer with therapy transducer amplifier | |
| US4116239A (en) | Ultrasonic oxygenation instrument | |
| US20080097252A1 (en) | Ultrasound and Pressure Therapy Wound Care Device | |
| JPH01151452A (en) | Ultrasonic suction apparatus | |
| US20080319316A1 (en) | Combination Imaging and Therapy Transducer | |
| JPH0422351A (en) | Dissolutive therapy device | |
| WO2009083904A2 (en) | Ultrasound treatment of adipose tissue with fluid injection | |
| WO2012176567A1 (en) | Ultrasonic wave irradiation device and ultrasonic wave irradiation method | |
| JPH07213622A (en) | Chemical dosing device | |
| JPH0422350A (en) | Dissolutive therapy device | |
| JPH0417844A (en) | Dissolving therapy apparatus | |
| JP3192340B2 (en) | Ultrasound surgery device | |
| JPH11318917A (en) | Ultrasonic foreign matter eliminator | |
| JP2004223175A (en) | Tumor treatment apparatus | |
| WO2023102104A1 (en) | Sequencing and strategies for enhancing intravascular thrombus disruption with phase-change cavitation enhancing agents | |
| JPH01160545A (en) | Ultrasonic suction apparatus | |
| JPH042338A (en) | Ultrasonic melting treatment apparatus | |
| JPH0255052A (en) | Ultrasonic medical device | |
| JPH03289953A (en) | Dissolving medical curing device | |
| JPH03297470A (en) | Dissolving type medical treatment device |